Alaunos Therapeutics Files 8-K on Security Holder Matters
Ticker: TCRT · Form: 8-K · Filed: Jul 10, 2025 · CIK: 1107421
| Field | Detail |
|---|---|
| Company | Alaunos Therapeutics, INC. (TCRT) |
| Form Type | 8-K |
| Filed Date | Jul 10, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing, security-holders
TL;DR
Alaunos Therapeutics filed an 8-K detailing changes to security holder rights and upcoming votes.
AI Summary
Alaunos Therapeutics, Inc. filed an 8-K on July 10, 2025, reporting events as of July 3, 2025. The filing indicates material modifications to the rights of security holders and the submission of matters to a vote of security holders. It also includes financial statements and exhibits.
Why It Matters
This 8-K filing signals potential changes in the rights of Alaunos Therapeutics' security holders and upcoming votes, which could impact shareholder value and corporate governance.
Risk Assessment
Risk Level: medium — Filings related to material modifications of security holder rights and votes can introduce uncertainty and potential shifts in the company's structure or value.
Key Numbers
- 001-33038 — SEC File Number (Identifies the company's filing history with the SEC.)
- 84-1475642 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Alaunos Therapeutics, Inc. (company) — Registrant
- ZIOPHARM ONCOLOGY INC (company) — Former Company Name
- EASYWEB INC (company) — Former Company Name
- July 3, 2025 (date) — Earliest event reported date
- July 10, 2025 (date) — Filing date
FAQ
What specific material modifications to the rights of security holders are being reported?
The filing does not detail the specific modifications in the provided text, but indicates that such modifications have occurred as of July 3, 2025.
What matters are being submitted to a vote of security holders?
The filing states that matters are being submitted to a vote, but the specific proposals are not detailed in the provided excerpt.
When was Alaunos Therapeutics, Inc. previously known as ZIOPHARM ONCOLOGY INC?
The name change from ZIOPHARM ONCOLOGY INC to Alaunos Therapeutics, Inc. occurred on September 19, 2005.
What is the principal executive office address for Alaunos Therapeutics, Inc.?
The principal executive offices are located at 2617 Bissonnet St, Suite 233, Houston, TX 77005.
What is the SIC code for Alaunos Therapeutics, Inc.?
The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 10, 2025 regarding Alaunos Therapeutics, Inc. (TCRT).